Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWL2XD)

Drug Name

GSK2402968 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Duchenne dystrophy	8C70	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dystrophin messenger RNA (DMD mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Eteplirsen	DM2QBHP	Duchenne dystrophy	8C70	Approved	[3]
Drisapersen	DMWUN1S	Duchenne dystrophy	8C70	Phase 3	[4]
Suvodirsen	DMKGQF0	Duchenne dystrophy	8C70	Phase 2/3	[5]
PRO-044	DMFYABR	Duchenne dystrophy	8C70	Phase 2	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dystrophin messenger RNA (DMD mRNA)	TTWLFXU	DMD_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01480245) Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy. U.S. National Institutes of Health.
2	Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014 Oct;13(10):987-96.
3	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
4	PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy. Curr Opin Mol Ther. 2010 Aug;12(4):478-86.
5	Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694.
6	Update on neuromuscular disorders in pediatric orthopaedics: Duchenne muscular dystrophy, myelomeningocele, and cerebral palsy. J Pediatr Orthop. 2014 Oct-Nov;34 Suppl 1:S44-8.